Orexigen Therapeutics, Inc. (OREX) Q2 2012 Earnings Call August 7, 2012, 8:30 a.m. ET Executives Heather Turner – VP & General Counsel Mike Narachi – President and CEO Preston Klassen – SVP, Global Contrave Team Jay Hagen – Chief Business Officer Analysts Charles Duncan – JMP Securities Marko Kozul – Leerink Swann Steve Byrne (Tazine) – BoA/Merrill Lynch Christian Glennie – Edison Investments Charles Duncan – JMP Securities PresentationOperator
Welcome to the Q2 2012 Orexigen Therapeutics, Inc. earnings conference call. My name is Lorraine and I will be your operator for today's call. (Operator Instructions). I will now turn the call over Miss Heather Turner. Miss Tuner, you may begin. Heather Turner Hello, and thank you for joining us to discuss the company's second quarter 2012 financial results. I am joined on this call by Mike Narachi, Chief Executive Officer, Dr. Preston Klassen, Senior Vice President Development, Jay Hagen, Chief Business Officer, and McDavid Stilwell, Vice President of Corporate Communications and Business Development. This morning, we issued a press release that provides details of the company's second quarter financial results. Please note that all of the information discussed on this call this morning is covered under the Safe Harbor provisions of the Private Securities Litigation Reform act. I caution listeners that during this call, the company's management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and the company's SEC filings including the form 10-Q the company plans to file this week.